Tysabri and PML: Understanding the Long-Term Outlook

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Tysabri and PML

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection. This concern is grounded in decades of medical research that has shaped how we understand the balance between therapeutic benefit and potential harm. Here, we explain what PML is, how it is reported to the FDA, and what long-term monitoring involves.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's strongest safety alert, specifically addressing this risk. Clinical presentation and diagnosis of PML are critical for early intervention. PML is an opportunistic viral infection of the brain that usually occurs only in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Symptoms can include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking, memory, and personality. Diagnosis typically involves brain magnetic resonance imaging (MRI) showing characteristic white matter lesions, detection of JC virus DNA in cerebrospinal fluid by polymerase chain reaction (PCR), and sometimes brain biopsy. The FDA label instructs healthcare professionals to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Pharmacology and Risk Factors for PML

The pharmacology of Tysabri and its link to PML are well established. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus in the brain, allowing the virus to reactivate and cause PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a central issue in legal and settlement considerations. The FDA label includes a boxed warning that clearly states Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that patients be enrolled in the TOUCH Prescribing Program, a restricted distribution program designed to manage the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read the Medication Guide, understand the risks, and complete and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, particularly for patients with anti-JCV antibodies or those on long-term therapy.

Settlement Considerations for California Tysabri PML Cases

Settlement-related considerations for affected patients often involve evaluating whether the manufacturer provided sufficient information about PML risk and whether the patient's specific risk factors were properly assessed and communicated. The timeline between Tysabri exposure and documented harm is variable. PML can occur after a few months to several years of treatment. The FDA label notes that the duration of treatment with Tysabri prior to onset of herpes infections ranged from a few months to several years, and similar variability is observed for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once PML develops, it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA Adverse Event Reporting System (FAERS) data show that the most frequently reported adverse events for Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, and drug ineffective (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they underscore the range of serious outcomes associated with the drug. For patients in California who have developed PML after Tysabri treatment, legal and settlement considerations may include the adequacy of warnings, the presence of risk factors, and the timing of diagnosis. The boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but individual cases may involve questions about whether these measures were sufficient. Settlement amounts can vary based on the severity of disability, medical expenses, lost income, and pain and suffering. Patients and their families should consult with legal counsel experienced in pharmaceutical injury cases to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What should I do if I or a loved one developed PML after taking Tysabri in California?

Seek immediate medical care and consult a California attorney experienced in pharmaceutical injury cases. Legal evaluation may consider adequacy of warnings, risk factors, and timing of diagnosis. Settlement amounts vary based on disability, expenses, and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.